Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide.
Short Term Liabilities: CTSO's short term assets ($22.4M) exceed its short term liabilities ($9.3M).
Long Term Liabilities: CTSO's short term assets ($22.4M) exceed its long term liabilities ($12.6M).
Debt to Equity History and Analysis
Debt Level: CTSO's debt to equity ratio (223%) is considered high.
Reducing Debt: Insufficient data to determine if CTSO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: CTSO has a low level of unsold assets or inventory.
Debt Coverage by Assets: CTSO's debt is covered by short term assets (assets are 1.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CTSO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CTSO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Cytosorbents's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CTSO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CTSO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTSO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTSO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTSO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Cytosorbents's salary, the management and board of directors tenure and is there insider trading?
6.7yrs
Average management tenure
CEO
PhillipChan(49yo)
10.9yrs
Tenure
US$1,247,295
Compensation
Dr. Phillip P. Chan, M.D., Ph.D. has been the Chief Executive Officer of Cytosorbents Corporation since January 2009 and serves as its President. Dr. Chan serves as a Partner of NJTC Venture Fund. He co-fo ...
CEO Compensation Analysis
Compensation vs Market: Phillip's total compensation ($USD1.25M) is above average for companies of similar size in the US market ($USD530.45K).
Compensation vs Earnings: Phillip's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
6.7yrs
Average Tenure
61yo
Average Age
Experienced Management: CTSO's management team is seasoned and experienced (6.7 years average tenure).
Board Age and Tenure
8.1yrs
Average Tenure
71yo
Average Age
Experienced Board: CTSO's board of directors are considered experienced (8.1 years average tenure).
Insider Trading
Insider Buying: CTSO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
BuyUS$11,03010 Dec 19
Kathleen Bloch
Entity
Individual
Role
Chief Financial Officer
CFO & Secretary
Shares
3,000
Max Price
US$3.68
BuyUS$59,40006 Dec 19
Phillip Chan
Entity
Individual
Role
Chief Executive Officer
CEO, President & Director
Shares
16,500
Max Price
US$3.60
BuyUS$4,27026 Nov 19
Kathleen Bloch
Entity
Individual
Role
Chief Financial Officer
CFO & Secretary
Shares
1,000
Max Price
US$4.27
BuyUS$31,39516 Aug 19
Kathleen Bloch
Entity
Individual
Role
Chief Financial Officer
CFO & Secretary
Shares
6,500
Max Price
US$4.83
BuyUS$8,27313 Aug 19
Kathleen Bloch
Entity
Individual
Role
Chief Financial Officer
CFO & Secretary
Shares
1,500
Max Price
US$5.52
BuyUS$19,47614 May 19
Kathleen Bloch
Entity
Individual
Role
Chief Financial Officer
CFO & Secretary
Shares
3,000
Max Price
US$6.49
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.9%.
Management Team
Vince Capponi (61yo)
Chief Operating Officer
Tenure: 14.4yrs
Compensation: US$1.08m
Kathy Bloch (64yo)
CFO & Secretary
Tenure: 6.6yrs
Compensation: US$953.58k
Phillip Chan (49yo)
CEO, President & Director
Tenure: 10.9yrs
Compensation: US$1.25m
Robert Bartlett (80yo)
Co-Chairman of Cardiac Surgery Advisory Board & Consultant
Tenure: 2.5yrs
Compensation: US$97.32k
Christian Steiner
Vice President of Sales & Marketing
Tenure: 7.5yrs
Chris Cramer
Vice President of Business Development
Tenure: 6.7yrs
Eric Mortensen (60yo)
Chief Medical Officer
Tenure: 2.8yrs
Compensation: US$780.07k
Board Members
Al Kraus (75yo)
Chairman of the Board
Tenure: 10.9yrs
Compensation: US$184.83k
Alan Sobel (58yo)
Independent Director
Tenure: 5.1yrs
Compensation: US$100.18k
Phillip Chan (49yo)
CEO, President & Director
Tenure: 10.9yrs
Compensation: US$1.25m
Edward Jones (71yo)
Independent Director
Tenure: 12.7yrs
Compensation: US$91.38k
Robert Bartlett (80yo)
Co-Chairman of Cardiac Surgery Advisory Board & Consultant
Tenure: 2.5yrs
Compensation: US$97.32k
John Kellum
Member of Critical Care Advisory Board
Tenure: 0yrs
Ronald Maier
Chairman of the Trauma Advisory Board
Tenure: 0yrs
Mitchell Cohen
Member of Trauma Advisory Board
Tenure: 0yrs
Raul Coimbra
Member of Trauma Advisory Board
Tenure: 0yrs
Joseph Zwischenberger
Chairman of Cardiac Surgery Advisory Board
Tenure: 5.3yrs
Company Information
Cytosorbents Corporation's company bio, employee growth, exchange listings and data sources
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incor ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/13 00:07
End of Day Share Price
2019/12/12 00:00
Earnings
2019/09/30
Annual Earnings
2018/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.